Oklo stock tumbles as Financial Times scrutinizes valuation
Jeffrey Alan Hawkins, President and CEO of Quantum-Si Inc (NASDAQ:QSI), sold a total of 21,286 shares of Class A Common Stock on September 22 and 23. The sales, executed in two tranches, totaled approximately $35,309. The transaction comes as QSI shows strong momentum, with the stock up nearly 28% in the past week and maintaining a solid financial health score according to InvestingPro analysis.
On September 22, Hawkins sold 10,643 shares at a weighted average price of $1.6826, with prices ranging from $1.64 to $1.72. The following day, September 23, he sold another 10,643 shares at a weighted average price of $1.635, with prices ranging from $1.57 to $1.79. The company, currently valued at $327 million, holds more cash than debt on its balance sheet, though it’s currently trading above its Fair Value based on InvestingPro’s comprehensive analysis of 10+ key metrics.
The sales were executed pursuant to a mandatory sell-to-cover provision for required tax withholdings related to the vesting of restricted stock units. Following these transactions, Hawkins directly owns 2,601,725 shares of Quantum-Si Inc. Get deeper insights into QSI’s valuation, financial health, and growth prospects with the exclusive Pro Research Report, available on InvestingPro.
In other recent news, Quantum-Si Incorporated reported its financial results for the second quarter of 2025. The company announced an earnings per share (EPS) of -$0.16, which was slightly below analysts’ forecast of -$0.14. Despite this, Quantum-Si achieved a revenue surprise of 15.7% over expectations, although the actual revenue of $591,000 did not meet all estimates. In addition to its financial disclosures, Quantum-Si launched its V4 Sequencing Kit, which is compatible with both Platinum and Platinum Pro instruments. This new kit enhances protein analysis capabilities by improving sequencing coverage and recognizing specific amino acids more effectively. These developments are part of Quantum-Si’s ongoing efforts to advance its technological offerings. The company continues to focus on expanding its product capabilities in the competitive sequencing market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.